Turk J Med Sci. 2014;44(2):261-6.
To determine the relationship between androgen receptor (AR) gene polymorphism and prostate cancer in our society.
Thirty-nine patients diagnosed with prostate cancer and 34 benign prostatic hyperplasia (BPH) patients who were diagnosed in 2010 met the study criteria. The inclusion criteria included patients whose diagnosis was confirmed with a biopsy, with the presence of adequate pathologic material for review, between the ages of 40 and 80, and who were healthy men without a family history of prostate cancer. The exclusion criteria excluded men diagnosed with another cancer and those who had kin with a history of prostate cancer. A direct DNA sequencing method was utilized for detection of polymorphisms.
CAG repeat length varied from 13 to 28 (mean: 21.67) for the BPH group and 12 to 28 (mean: 21.74) for the prostate cancer group. Prostate-specific antigen (PSA) density and the androgen receptor (AR) CAG repeat had a statistically significant negative correlation in the BPH group. A statistically significant difference was associated between AR CAG repeat and PSA density.
Randomized prospective studies should be planned with larger patient and control groups and with more variables, which may open new horizons in prostate cancer screening and early detection.
在本研究人群中，确定雄激素受体（AR）基因多态性与前列腺癌之间的关系。
2010 年，符合研究标准的 39 例前列腺癌患者和 34 例良性前列腺增生（BPH）患者被纳入研究。纳入标准为：经活检证实诊断，有足够的病理材料进行回顾性分析，年龄在 40-80 岁之间，健康的男性，无前列腺癌家族史。排除标准为：诊断为另一种癌症的患者和有前列腺癌家族史的亲属。采用直接 DNA 测序法检测多态性。
BPH 组 CAG 重复长度为 13-28（平均 21.67），前列腺癌组为 12-28（平均 21.74）。BPH 组前列腺特异性抗原（PSA）密度与雄激素受体（AR）CAG 重复呈显著负相关。AR CAG 重复与 PSA 密度之间存在显著差异。
应计划进行更大规模的患者和对照组的随机前瞻性研究，并纳入更多变量，这可能为前列腺癌筛查和早期检测开辟新的前景。
